Skip to content

Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease

A Random Controlled Clinical Trial:l Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01454726
Acronym
TCDMD
Enrollment
27
Registered
2011-10-19
Start date
2011-01-31
Completion date
2011-11-30
Last updated
2012-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniere's Disease

Keywords

Dizziness, Meniere's disease, Diaoshi Jifa therapy

Brief summary

The hypothesis of this study is that DiaoShi Jifa reduces the symptoms, such as dizziness in patients with Meniere's disease.

Detailed description

Created by Dr. Diao, DiaoShi Jifa is a well-known traditional Chinese Medicine approach to treat dizziness in patients with chronic diseases. The investigators designed this randomized clinical trial to examine whether Diaoshi Jifa significantly decreases dizziness in patients with Meniere's disease. There are 2 arms in this trial: One arm is DiaoShi Jifa plus conventional Western medical treatment, another is conventional Western medical treatment only. The dizziness handicap inventory (DHI) will be used to evaluate the treatment effect.

Interventions

OTHERDiaoshi Jifa therapy plus the Western medical treatment.

Diaoshi Jifa treatment

OTHERdrug

the Western medical treatment alone.

Sponsors

Beijing Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Beijing Administration of Traditional Chinese Medicine Bureau
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of probable Meniere's disease 2. Must be able to receive manual treatment 3. Dizziness Patients receiving other treatment longer than 5 days before entering the study.

Exclusion criteria

1. Patients with critical illness of internal medicine and surgery 2. Patients with spinal disease or other conditions that cannot receive manual treatment.

Design outcomes

Primary

MeasureTime frameDescription
Change in Dizziness Handicap Inventory (DHI) Questionnaire Score0 and 24 hoursdizziness Handicap Inventory (DHI) evaluates the self-perceived handicapping effects imposed by vestibular system disease. We employed the final version of DHI, which contains 25 items including 7 physical questions, 9 functional questions and 9 emotional questions. DHI has a total score of 100 points (4 points for each item). Higher scores indicate more severe handicap. Thus the maximum score for DHI is 100, while the minimum core is 0.

Countries

China

Participant flow

Recruitment details

recruitment period: Jan 1, 2011-November 30, 2011 recruitment location: Department of Neurology, Xuan Wu Hospital of Capital Medical University

Pre-assignment details

A total of 27 patients were enrolled and randomly attributed to either experimental or control group.

Participants by arm

ArmCount
Experimental Group
receiving both Diaoshi Jifa therapy and the Western medical treatment.
16
Control Group
receiving the Western medical treatment alone.
11
Total27

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject01

Baseline characteristics

CharacteristicControl GroupExperimental GroupTotal
Age, Categorical
<=18 years
0 Participants1 Participants1 Participants
Age, Categorical
>=65 years
1 Participants1 Participants2 Participants
Age, Categorical
Between 18 and 65 years
10 Participants14 Participants24 Participants
Age Continuous54.00 years
STANDARD_DEVIATION 8.91
49.75 years
STANDARD_DEVIATION 12.63
51.48 years
STANDARD_DEVIATION 11.27
Region of Enrollment
China
11 participants16 participants27 participants
Sex: Female, Male
Female
5 Participants11 Participants16 Participants
Sex: Female, Male
Male
6 Participants5 Participants11 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 160 / 10
serious
Total, serious adverse events
0 / 160 / 10

Outcome results

Primary

Change in Dizziness Handicap Inventory (DHI) Questionnaire Score

dizziness Handicap Inventory (DHI) evaluates the self-perceived handicapping effects imposed by vestibular system disease. We employed the final version of DHI, which contains 25 items including 7 physical questions, 9 functional questions and 9 emotional questions. DHI has a total score of 100 points (4 points for each item). Higher scores indicate more severe handicap. Thus the maximum score for DHI is 100, while the minimum core is 0.

Time frame: 0 and 24 hours

Population: Among the 27 participants enrolled in the study, one participant quitted the study before treatment application. Twenty-six patients fulfilled all the procedures and were eligible for the full analysis.

ArmMeasureValue (MEAN)Dispersion
Experimental GroupChange in Dizziness Handicap Inventory (DHI) Questionnaire Score10.25 units on a scaleStandard Deviation 9.77
Control GroupChange in Dizziness Handicap Inventory (DHI) Questionnaire Score49.6 units on a scaleStandard Deviation 20.5

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026